No Major Impact to Sarepta (SRPT) Seen on Eteplirsen Panel Delay; PDUFA Date Likely Pushed Out
Tweet Send to a Friend
RBC reaffirms Sarepta Therapeutics, Inc. (Nasdaq: SRPT) at Sector Perform with a price target of $15 following news late Wednesday ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
